Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Mark Bartlett who wrote (1657)	4/17/1999 7:41:00 AM
From: Tom Drolet	Read Replies (2) \| Respond to of 14101

Mark: If I were the type of person that was concerned about Canadian Health Branch mismanagement, I might even say "gosh darn -wish they would look after DMX -Pennsaid as well as they follow the leader to the south at the FDA". Might as well hand over the job to the FDA-then we can loose a little more identity, control and pride of Canadian superior invention and industry. This was featured in the G&M prominently on Friday--ROB. Oh dear! Guess I am like them after all-- just role over and allow advantage to the juggernauts of the USA. Ah, to hell with it--BUNCH OF TWITS! New drug for arthritis expected to take off Therapy doesn't cause stomach bleeding Friday, April 16, 1999 Canadian Press Toronto -- A new arthritis drug is expected to outpace Viagra in demand when it hits the Canadian market by the end of this month, its promoters say. Pharmaceutical company Pfizer Inc., which makes the anti-impotence medication and is also involved in the Canadian launch of arthritis drug Celebrex, makes this predication because the new treatment doesn't cause stomach bleeding. Other arthritis therapies do have this side effect and have been linked to nearly 2,000 deaths a year in Canada. Celebrex will drastically change treatment choices, said Bill Bensen, a rheumatologist based in Hamilton, Ont., who led Canadian trials of the drug. Celebrex "altered my life and lifestyle a thousandfold," said Anne Malo, a 48-year-old pianist who once had to give up her work because of arthritis. She has been on the medication -- which costs about the same as other prescription anti-inflammatories -- for two years and it has allowed her to take up music again, Ms. Malo said at a news conference yesterday. She has been under Dr. Bensen's care as part of trials that involved 1,900 Canadians. At 34, after a bout with a virus causing chronic fatigue, Ms. Malo's joint pain and swelling got worse. She couldn't slide on pantyhose, do up her bra or even slip into shoes, let alone care for her three young sons or play piano at the ballet school where she worked. "It's debilitating physically, but mentally as well; you know you don't have a future," she said. Ms. Malo is now out of her wheelchair, running, swimming and resuming her career. Dr. Bensen calls arthritis, which has about 100 forms, the "sleeping giant of health care" that will awaken as the population ages. Arthritis affects about four million Canadians of all ages, although it's largely linked with those over 50. It's the main reason workers go on long-term disability. The most common arthritis is osteo, in which cartilage-protecting bone wears down and causes pain, inflammation and loss of movement. Rheumatoid arthritis is more puzzling because it's linked with a damaged immune system. The lining of joints and organs becomes inflamed, and the disease can cause weakness, fatigue and weight loss. Drug therapy, from over-the-counter pain relievers such as Aspirin and ibuprofen to prescription drugs, has been controversial. In fact, some experts believe that long-term use of anti-inflammatories, which treat only symptoms of the disease, may make it progress faster. One reason is patients on painkilling medication may take more than they should, further breaking down cartilage and joints. --------------------------------------------------------------------------------